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In humans, it is not possible to obtain experimental evidence of when a cancer begins to metastasize.
The purpose of this study was to estimate the time of onset of metastatic dissemination in cutaneous melanoma
using a model based on its growth rate (GR). The critical time of onset of metastatic dissemination below which
no cases of fatal melanomas were seen may be described with a potential function in which this time is
inversely proportional to the GR. The critical time of development beyond which a melanoma may metastasize
presents great variation. This time was just 1 month for those melanomas with a fast GR, whereas it was over
5 years for those with a very slow GR. Quantitatively, the fastest-growing melanomas began metastasizing with
a greater thickness than the slowest-growing melanomas. A correlation exists between the critical time of
onset of metastatic potential and the GR of the melanoma. These results may well have relevance to the
understanding of mechanisms of tumor dissemination and for the design of future studies on melanomas,
irrespective of whether they are basic studies on biomolecular mechamisms or clinical studies.
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INTRODUCTION
The incidence of cutaneous melanoma (CM) has increased
greatly over recent decades in developed countries, including
Spain (Saenz et al., 2005). A series of factors are associated
with a worse prognosis at diagnosis, such as tumor thickness,
the presence of ulceration, the presence of mitosis, or lymph
node involvement (Balch et al., 2009).
With regard to the metastatic process, no experimental
evidence yet exists of when a tumor actually begins to
metastasize. In the past, retrospective estimates were made in
some tumors of both metastasis (Tubiana et al., 1975) and the
primary tumor based on the doubling time (Bauer et al.,
1980). These estimations concluded that the metastatic
process occurred with very small tumor sizes, even as small
as a millimeter (von Fournier et al., 1980).
In the case of CM, current data suggest that, whereas some
cases appear and metastasize very quickly (del Boz et al.,
2009), others grow extremely slowly, with metastasis appear-
ing many years later (Nozaki et al., 1999). In fact, the time of
appearance of the metastasis can be represented in terms of the
growth rate (GR) of the melanoma, with the time of appearance
of metastasis being inversely proportional to the GR of the
melanoma (Tejera-Vaquerizo et al., 2011), with the GR being a
measurement defined by the tumor thickness per unit of time.
This study involved a quantitative analysis of the time at
which metastatic dissemination started in CM using a model
based on the GR of the primary CM. The working hypothesis
was that fast-growing melanomas metastasize sooner than
slow-growing melanomas. The analysis was performed with a
sufficient number of cases, each one of which was characterized
by a particular clinical time of development and GR, enabling a
mathematical equation to be designed to which the critical time
of onset of metastatic dissemination of the CM was adjusted.
RESULTS
The maximum regression coefficient value was obtained for
the potential function, which related the dependent variables
td (critical time of development of a fatal melanoma) and
independent GR using the following expression:
td ¼ aGRb ð1Þ
Where a and b are two adjustable parameters. In our case, the
results obtained were as follows:
a ¼ 2:5 0:24
b ¼ 0:7 0:02
Although this method presents a series of limitations (as
discussed below), this analysis permits the experimental data
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to be treated quantitatively. Thus, Table 1 shows the
numerical values of the various critical times obtained with
the Eq (1) for different GR values. For the fast-growing
melanomas of 3.25 mm per month, the time beyond which
they may begin to metastasize is just 1.1 (1–1.2) months. This
time increases with the reduction in GR. For a melanoma that
grows at a rate of 0.5 mm per month this time is 4.1 (4.5–3.7)
months. This time is about 1 year for the melanomas with a
GR of 0.1 mm per month and increases to several years for
the very slow-growing melanomas, such as those that grow
up to 0.01 mm per month, where the calculated critical time
is 62 (70–56) months.
Table 1 also shows the critical thickness of the melanoma
corresponding to each GR value. This thickness is defined as
that of the CM at the time its metastatic potential was
realized; it is therefore calculated as the product of the GR
and the critical time given by the Eq (1). Paradoxically, the
faster-growing melanomas began to be metastatic at a much
greater thickness than the slower-growing melanomas.
Thus, a melanoma growing at 3.25 mm per month starts
becoming metastatic at a thickness of 3.5 (3.9–3.2) mm. On
the other hand, at the bottom part of the table we see that
a slow-growing melanoma of 0.01 mm per month requires a
thickness of just 0.6 (0.7–0.6) mm to become metastatic.
In the replica of the study undertaken in 903 patients from
the Instituto Valenciano de Oncologı´a (IVO), a diagram was
designed showing the time of development versus GR for the
cases of CM (Figure 3). Similarly, the tumors were categor-
ized according to their time of development as either fatal
melanomas (n¼ 100) or nonfatal melanomas (803). A total of
five cases were selected for the nonlinear regression (arrows).
In this case, the equation that best explained the relation-
ship between the td and the independent GR variables was
also a potential function (1), where the parameters a and b
were as follows:
a ¼ 1:8 0:4
b ¼ 0:7 0:1
As can be seen in Table 1, the data for the critical times were
all very similar to the data obtained using the previous
database. The fast-growing melanomas of 3.25 mm per
month started to metastasize within 1 month (0.8–1.2); those
with a GR of 0.5 mm per month started at 3 (2.3–3.6) months;
Table 1. Critical time of development and tumor thickness for the various melanoma growth rate values
HVV IVO
Growth rate (mm per month)
Critical time of
development (months)
Tumor thickness
(mm)
Critical time of
development (months)
Tumor thickness
(mm)
3.25 1.1 (1–1.2) 3.6 (3.2–3.9) 0.8 (0.6–1) 2.6 (2–3.2)
3 1.2 (1–1.3) 3.5 (3.1–3.8) 0.8 (0.6–1) 2.5 (2–3.2)
2.75 1.2 (1.1–1.4) 3.4 (3.1–3.7) 0.9 (0.7–1.1) 2.4 (1.9–3)
2.5 1.3 (1.2–1.4) 3.3 (3–3.6) 0.9 (0.7–1.2) 2.3 (1.8–2.9)
2.25 1.4 (1.3–1.6) 3.2 (2.9–3.5) 1 (0.8–1.3) 2.2 (1.8–2.8)
2 1.5 (1.4–1.7) 3.1 (2.8–3.4) 1.1 (0.9–1.4) 2.2 (1.7–2.7)
1.75 1.7 (1.5–1.9) 3 (2.7–3.2) 1.2 (0.9–1.5) 2.1 (1.6–2.6)
1.5 1.9 (1.7–2.1) 2.8 (2.6–3.1) 1.4 (1–1.7) 2 (1.5–2.4)
1.25 2.1 (1.9–2.3) 2.7 (2.4–2.9) 1.6 (1.2–1.9) 1.9 (1.5–2.3)
1 2.5 (2.3–2.7) 2.5 (2.3–2.7) 1.8 (1.4–2.2) 1.8 (1.4–2.2)
0.75 3.1 (2.8–3.4) 2.3 (2.1–2.5) 2.2 (1.7–2.7) 1.7 (1.3–2.1)
0.5 4.1 (3.7–4.5) 2 (1.8–2.2) 3 (2.3–3.6) 1.5 (1.2–1.8)
0.4 4.7 (4.3–5.2) 1.9 (1.7–2.1) 3.4 (2.6–4.2) 1.4 (1.1–1.7)
0.35 5.2 (4.7–5.7) 1.8 (1.6–2) 3.8 (2.8–4.7) 1.3 (1–1.7)
0.3 5.8 (5.2–6.4) 1.7 (1.6–1.9) 4.2 (3.2–5.2) 1.2 (0.9–1.6)
0.25 6.6 (6–7.2) 1.6 (1.5–1.8) 4,8 (3.5–6) 1.2 (0.9–1.5)
0.2 7.7 (7–8.5) 1.5 (1.4–1.7) 5.6 (4–7.1) 1.1 (0.8–1.5)
0.15 9.4 (8.5–10.4) 1.4 (1.3–1.6) 6.8 (4.8–8.8) 1 (0.7–1.3)
0.1 12.5 (11–14) 1.3 (1.1–1.4) 9 (6.2–11.9) 0.9 (0.6–1.2)
0.05 20 (18–22) 1 (0,9–1.1) 15 (9.2–20.1) 0.7 (0.5–1)
0.02 33 (30–37) 0.8 (0.7–0.9) 24 (13.6–34) 0.6 (0.4–0.8)
0.01 62 (56–70) 0.6 (0.6–0.7) 45 (22–68) 0.5 (0.3–0.7)
Abbreviations: HVV, Hospital Virgen de la Victoria (Malaga); IVO, Instituto Valenciano de Oncologı´a (Valencia).
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and the critical time for the melanomas with a very slow GR
of 0.01 mm per month was 45 (22–68) months.
Logically, the calculated critical thickness was also greater
for the melanomas with a higher GR. The critical thickness for
the melanomas with a GR of 3.25 mm per month was 2.6
(2–3.2) mm, whereas for the melanomas with a very slow GR
of 0.01 mm per month it was 0.5 (0.3–0.7) mm.
DISCUSSION
One of the basic questions in the study of malignant tumors
is ‘‘When does a cancer metastasize?’’. Unfortunately, in
humans it is not possible to obtain experimental evidence to
answer this question. Nevertheless, by using the tumor volume
doubling time of the primary tumor and its metastases, it is
possible with retrospective extrapolation to indirectly obtain
an approximate time of dissemination, assuming an exponen-
tial tumor growth (Collins et al., 1956; Breur, 1966; Tubiana
et al., 1975). Most of these studies showed that metastasis
started years before the internal tumor was diagnosed.
The case of melanoma, however, is different, as its clinical
development can be seen from the time it is still very small.
This, then, enables its GR to be calculated. The concept of
GR in the study of primary melanoma is very recent, and it is
based on temporal data reported by the patients themselves.
Although this is subjective, the parameter GR is still relevant
because it has been associated with a more aggressive
phenotype, such as thicker melanomas, with more mitoses,
ulcerated or amelanotic (Liu et al., 2006); indeed, it has even
been associated with a worse prognosis (Tejera-Vaquerizo
et al., 2010).
In this study, by representing the GR according to the
development time of the various lesions up to the time of
surgery, it has been possible to estimate the time of onset of
the metastatic capacity of the melanoma.
The main limitation of this study concerns the fact that the
time of development of the lesions is based on the
information provided by the patients. This information,
therefore, is conditioned by such factors as the localization,
sex, age, or psychological state of the patient (Grob et al.,
2002). Nevertheless, this error related to the time of
development as reported by the patient did not appear to
be very great in a small sample in which the response of the
patients was reevaluated several months later (Baade et al.,
2006). In addition, the GR of CM correlates significantly with
both the mitotic index and markers of cell cycle and mitosis,
as are Ki-67 and phosphorylated histone H3 (Liu et al., 2008).
The GR of a tumor remains constant for long periods of
time, as shown by Collins et al. (1956) over 50 years ago in
studies on pulmonary metastases of various primary tumors.
Moreover, a correlation exists between the kinetics of the
primary tumor and the kinetics of its metastasis (Kusama
et al., 1972). Consequently, we can assume a priori that the
invasion of a melanoma occurs at a constant rate.
Another possible limitation concerns the presence of
regression in the histological study of the melanomas, which
could result in underestimating the true thickness of the
lesions. However, given the difficulty to determine what
effect the intensity of this regression might cause on the true
thickness, we have preferred not to exclude these melanomas
(Requena et al., 2009).
Despite the fact that the critical time calculated from the
start of the metastatic capacity of the melanoma is very
similar in both databases, it is slightly sooner in the IVO
figure because of a lower coefficient (1.8 vs. 2.5), which
affects the results seen in Table 1. This difference may be due
to the cases selected for the calculation, which were not
completely homogenous. The IVO calculation included one
case that proved fatal and that was just 0.5 mm thick (data not
shown), whereas in the Hospital Virgen de la Victoria (HVV)
calculation the smallest case was 0.8 mm. Furthermore, the
calculation of the GR implies considering the variable month
as a discrete variable for the unit of months, as was originally
described, and this may have a special repercussion on the
thick and fast-growing melanomas, resulting in a small error
in the calculation of the GR.
The first implication of this study concerns the context of
early diagnosis. Not least, because the term ‘‘early’’ is
incorrect for many tumors that have probably been growing
for years before they actually become visible (Friberg and
Mattson, 1997). In the case of melanoma, our study provides
greater precision to the definition of the concept ‘‘early
melanoma’’. ‘‘Early’’ surgery results in a logical reduction of
mortality only if the melanoma is excised before metastatic
dissemination occurs. This work shows that dissemination of
fatal cases may occur long before the melanoma is removed.
The success of certain secondary prevention programs
in melanoma has been evaluated according to the reduction
in the percentage of thick melanomas with a certain size,
usually between 1.5 and 2 mm (MacKie et al., 2003;
Demierre et al., 2005). Our findings suggest that the
maximum thickness a secondary prevention program should
aim at is not, in fact, a fixed value. This thickness depends on
the critical time of development, which in turn depends on
the GR. For example, our data suggest that a melanoma of
1.5 mm thickness growing faster than 0.4 mm per month can
be considered early, whereas it would not be early if the GR
was below 0.4 mm per month.
From our results, we can consider a real ‘‘early mela-
noma’’ to be that which is below the curve calculated for
each database where no fatal melanomas were seen. Thus,
Table 2 specifies the number of cases according to the tumor
thickness that can be considered as early melanomas. For the
HVV database, these comprised 71.6% of the melanomas
smaller than 1 mm, 15.7% of the melanomas between 1.01
and 2 mm, 14.3% of the melanomas between 2.01 and 4 mm,
and no case for melanomas larger than 4 mm. The
corresponding figures in the IVO database were 46.3, 14.7,
and 7%, and one case in the melanomas larger than 4 mm.
Second, this study reports an apparently paradoxical
situation. The fast-growing melanomas were seen to require
a greater thickness than the slow-growing tumors before they
became metastatic. These results are compatible with current
experimental evidence. In fact, survival curves of melanoma
show the presence of an important percentage of thin and
intermediate melanomas that remain free from long-term
disease (90% survival for melanomas o1 mm and 70%
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survival for melanomas 1.01–2 mm) (Balch et al., 2009). The
fact that fast-growing tumors begin to show a metastatic
capacity at a greater thickness would explain, at least in part,
these survival curves, particularly in the thin melanomas.
As far as we are aware, only one research group has
published data concerning this question (Michaelson et al.,
2005). These authors established that the probability of a
tumor disseminating does not remain constant as its volume
increases. Rather, this probability falls with increasing tumor
size. Thus, they calculated a risk of 1 dissemination event for
each 500 tumor cells for melanomas of 0.1 mm thickness,
whereas for melanomas of 5 mm this probability was
calculated to be 1 dissemination event for each 108 tumor
cells. These observations suggest that metastatic dissemina-
tion is more the result of mechanical phenomena than
genetic changes over successive stages, in what has become
known as the ‘‘metastatic cascade’’ (Geiger and Peeper,
2009). This relationship between the probability of dissemi-
nation of a cell (p) and the number of cells in the tumor (N)
adjusts well to the equation p¼ aNb, where a is a constant
for each tumor and b is a coefficient, whose value is
approximately 2/3 (Michaelson et al., 2009).
From our study, it can be deduced that the time of
development of a melanoma may condition its dissemination.
Thus, we see that thin melanomas that have metastasized are
slow melanomas with a prolonged time of development.
Another limitation of this study concerns the follow-up
time. The median follow-up period was 55 months for the
patients at the HVV and 49 months for those at the IVO,
implying that some cases initially identified as nonfatal would
prove fatal given sufficient follow-up. This occurs in around
10% of localized invasive melanomas that metastasize after
8 years of follow-up (Brauer et al., 2010) and is probably
related to thin melanomas, as shown in dermatoscopic
follow-up (Argenziano et al., 2010). For this reason, and
despite the fact that the two functions of the critical time of
development of metastasis in both databases were similar, we
cannot rule out the possibility that these functions might
change with a longer follow-up.
Conclusions
In conclusion, this study estimates the time at which a
melanoma may start developing its metastatic capacity. This
finding has relevance in the context of ‘‘early melanoma’’
and its epidemiologic and therapeutic implications. The study
also shows that melanomas start metastasizing at differing
thicknesses, depending on their GR. These results may well
have relevance for the design of future studies on melanomas,
irrespective of whether they are basic studies on biomole-
cular mechanisms or clinical studies. Nevertheless, given the
limitations of this study, our findings should be confirmed in
further prospective studies.
MATERIALS AND METHODS
Patient population
All patients with CM attended the Dermatology Department of the
Virgen de la Victoria Hospital between 1990 and 2004 were
included in the study. These data were obtained from the department
database, which has prospectively collected clinical and pathologi-
cal data since 1990. As the aim of the study was to analyze
quantitatively whether there exists a critical evolution time for the
start of metastatic dissemination depending on the GR, the study
included all the patients, irrespective of the CM stage at diagnosis.
From an initial population of 456 patients, 23 patients with
melanoma in situ were excluded as they lacked a risk of relapse.
Patients were also excluded if they presented two or more invasive
melanomas (n¼ 10), as well as those who had an immunosuppres-
sive disorder (n¼ 2). Thus, the final study included a total of 416
patients (Table 3).
The retrospective cohort chosen to replicate the study belonged
to the Instituto Valenciano de Oncologı´a (IVO). This database has
been described in detail in earlier publications (Nagore et al., 2008,
2009). It includes patients seen at this department between 2000 and
2010, independently of the stage at diagnosis, from an initial
population of 1,200 patients. Finally, using the same selection
criteria, a total of 903 patients were included (Table 3).
The follow-up protocol for patients at both centers comprised a
revision every 3 months for the first 2 years after diagnosis, then
every 6 months up to 5 years, and thereafter annually. The protocol
for each visit included a physical examination of all the skin, lymph
node areas and abdomen, and a blood test, including lactate
dehydrogenase. A chest radiograph and abdominal ultrasound were
performed at the start, every 6 months for the first 2 years and
annually up to 5 years. Other imaging studies, such as computed
tomography or magnetic resonance, were only conducted if a
possible metastasis was detected at a control.
Table 2. Distribution of cases of melanoma above and below the critical time of development of fatal melanomas
according to tumor thickness
HVV IVO
Tumor thickness
(mm)
Below the critical time of
development (%)
Above the critical time of
development (%)
Below the critical time of
development (%)
Above the critical time of
development (%)
o1 121 (71.6) 48 (28.4) 114 (46.3) 132 (53.7)
1.01–2 14 (9.6) 75 (84.3) 21 (14.7) 122 (85.3)
2.01–4 11 (7.5) 66 (85.7) 7 (6.8) 96 (93.2)
44 0 (0) 47 (100) 1 (1.4) 72 (98.6)
Abbreviations: HVV, Hospital Virgen de la Victoria (Malaga); IVO, Instituto Valenciano de Oncologı´a (Valencia).
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For the initial staging of the lesions, at the HVV up until 2001
when the sentinel lymph node technique was introduced, the
assessment of the regional involvement was clinical or with
complementary studies.
Both databases fulfill the ethical requisites applicable, and
the study was approved by the ethics commissions of the two
centers.
Calculation of the GR
The GR was defined in accordance with the initial description (Grob
et al., 2002). In brief, this involves a rate that measures volume
increase per unit of time. As no accepted method exists to measure
tumor volume, the tumor thickness is used as a substitute value. The
variable ‘‘time’’ used in the calculation of the GR is defined as the
interval (in months) between the time that the patient or the family
first noticed the lesion in ‘‘de novo’’ cases or else noticed changes to
a previous lesion (D1) and the time at which the lesion was removed,
with its pathological report (D2). The GR was determined by the
index between the tumor thickness and the time in months, defined
as D2 minus D1.
In 27 of the Virgen de la Victoria Hospital cases, it was not
possible to calculate the GR as either the patient did not know the
time of development (n¼ 24) or because the tumor thickness was
unknown (n¼ 2), and in 1 case neither the development time of the
lesion nor the tumor thickness were known.
For the IVO, it was not possible to calculate the GR in 338 cases.
This was because the development time was not recorded in 300
patients or because the tumor thickness was unknown (n¼ 30); in
eight cases, both these factors were unknown.
Description of the model
As commented in the Introduction, the basic hypothesis of the model
supposed that the time taken by a melanoma to metastasize depends
on its GR, such that the faster the GR the sooner the tumor
metastasizes. This behavior is illustrated in Figure 1, which
represents the critical time for the development of metastasis for
CM with different GR.
To examine the validity of the hypothesis and its consequences, a
dispersion chart was designed showing the time of development
versus GR for the cases of CM. Assuming that the melanomas that
produce systemic metastasis are those that present a fatal course, the
CM were classified according to their evolution into fatal (n¼ 44)
and nonfatal (n¼ 372) melanomas. The median follow-up time of
these patients was 55 (2–210) months. This sort of diagram reveals
trends in the data, and study of these trends can suggest critical
values in the time of development above which cases of fatal
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Figure 1. Basic theory of the model. The time of start of metastatic
dissemination depends on the growth rate of the melanoma.
Table 3. Characteristics of the study population
HVV IVO
Variable N (%) N (%)
Age
Median (years) 50.7 55
Gender
Female 251 (60.3) 462 (51.2)
Male 165 (39.7) 441 (48.8)
Anatomical location
Head and neck 61 (14.7) 146 (16.2)
Trunk 150 (36.1) 366 (40.5)
Extremities 176 (42.3) 308 (34.1)
Hand/foot 29 (7) 80 (8.9)
Histological subtype
LMM 34 (8.2) 38 (4.2)
SSM 277 (66.6) 573 (63.5)
NM 67 (16.1) 193 (21.4)
ALM 20 (4.8) 47 (5.2)
Others 6 (1.4) 41 (4.5)
Stage
I 251 (60.3) 535 (59.3)
II 135 (32.5) 212 (23.5)
III 25 (6) 129 (14.2)
IV 5 (1.2) 13 (1.4)
Development of systemic metastasis
Yes 44 (10.5%) 100 (11%)
No 372 (89.5%) 803 (89%)
Median follow-up (months) 55 49
Total 416 903
Abbreviations: ALM, acral lentiginous melanoma; HVV, Hospital Virgen
de la Victoria (Malaga); IVO, Instituto Valenciano de Oncologı´a
(Valencia); LMM, lentigo maligna melanoma; NM, nodular melanoma;
SSM, superficial spreading melanoma.
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melanoma are seen (Mazumdar and Glassman, 2000). This
dispersion chart is shown in Figure 2, where the cases of fatal and
nonfatal melanoma are represented on a logarithmic scale according
to their GR and time of development. This figure shows that for each
GR value there is a critical time of development value, td, below
which the melanoma is not fatal. Alternatively, the fatal cases appear
for each GR for a development time above a certain critical value
that depends on the particular GR. These critical times are
represented in Figure 2 by a dashed line. Effectively, the time of
development is longer for the CM with slower GR than for those with
faster GR, which justifies the starting hypothesis.
The curve describing the critical time for the development of a
fatal melanoma was obtained by the following procedure. First, we
considered the cases of fatal CM with different GR, each selected
such that no fatal case was seen for any shorter time of development.
A total of five cases were selected (arrows). These five cases were
analyzed by nonlinear regression using the Levenberg–Marquardt
method (Levenberg, 1944) with various functional dependencies:
potential, exponential, and hyperbolic. The criteria used to choose
the adjustment function were greater statistical significance of the
regression parameters and a greater regression coefficient R2 value.
The calculations were made with SPSS, version 15.0 (Chicago, IL).
For the replica study using the IVO database with the same
methods, the melanomas were classified as fatal (n¼ 100) or
nonfatal (n¼ 803). A dispersion chart was made (Figure 3) and five
cases selected (arrows). They were also analyzed by nonlinear
regression.
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